CT-007 is under clinical development by First Condor Group and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I drugs for Gastric Cancer have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CT-007’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CT-007 overview
CT-007 is under development for the treatment of claudin 18.2 (CLDN18.2) positive solid tumors, gastric cancer, esophageal cancer and gastroesophageal (GE) junction cancer. The therapeutic candidate comprises of T-cells genetically modified to express chimeric antigen receptor (CAR) and acts by targeting cells expressing claudin 18.2. It is being developed based on second generation CAR-T technology.
First Condor Group overview
First Condor Group is a biotechnology company that is involved in cell storage, production, research and development, and promotion in the fields of cell therapy. The company is headquartered in Dongguan, Guangdong, China.
For a complete picture of CT-007’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
